Company: BDRX
Filing Date: 2025-06-27
Form Type: 424B3
Source: 0001214659-25-009731
Chunk: 3

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-06-27
Form: 424B3
Chunk 3
---
ammalian arget f apamycin) inhibitor. mTOR has been shown
to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during
tumorgenesis.

Tolimidone is an orally delivered, potent and selective inhibitor
of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural
tissues, liver, and adipose tissue. Tolimidone demonstrates glycemic control via insulin sensitization in animal models of diabetes and
has the potential to become a first in class blood glucose modulating agent.

MTX110 is a solubilised formulation of the histone deacetylase
(HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at
chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic
toxicity.

Biodexa is supported by three proprietary drug delivery technologies
focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff,
UK. For more information visit www.biodexapharma.com.

Forward-Looking Statements

Certain statements in this announcement may constitute “forward-looking
statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation.
All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements.
In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects”
or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions,
events or results “may”, “could”, “would”, “might” or “will be taken”, “occur”
or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties,
many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements
to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties
and other factors set out herein.

Reference should be made to those documents